Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027.
美国政府最近谈判医疗保险药品价格的举措引发了关于下一轮谈判可能针对哪些药品的猜测，该轮谈判定于2027年进行。
Last week, the Biden administration announced that Medicare's newly negotiated prescription drug prices are expected to save the U.S. government $6 billion in the first year alone.
上周，拜登政府宣布，医疗保险新谈判药品价格预计仅在第一年就能为美国政府节省60亿美元。
According to some analysts, Novo Nordisk A/S' (NYSE:NVO) blockbuster diabetes drug Ozempic might be included, along with several other well-known medications.
据一些分析师称，诺和诺德（Novo Nordisk A/S）的糖尿病疗法明星药物奥塞皮（Ozempic）可能会被纳入，以及其他几种知名药物。
Also Read: Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy.
另外阅读：诺和诺德Wegovy对心脏病患者的医疗保险覆盖存在困难。
These could include Pfizer Inc.'s (NYSE:PFE) cancer drugs Ibrance and Xtandi, GSK Plc's (NYSE:GSK) asthma treatment Trelegy Ellipta, Teva Pharmaceutical Industries Ltd.'s (NYSE:TEVA) Huntington's disease drug Austedo, and Abbvie Inc.'s (NYSE:ABBV) irritable bowel syndrome treatment Linzess.
这些药品可能包括辉瑞公司的癌症药物Ibrance和Xtandi，葛兰素史克公司（GSK）的哮喘治疗药物Trelegy Ellipta，梯瓦制药公司的亨廷顿病药物Austedo，以及艾伯维公司的肠易激综合征治疗药物Linzess。
The list would focus on drugs available since at least 2017, primarily those on which Medicare spends heavily.
该名单将重点关注至少自2017年以来可获得的药物，主要是医疗保险支出较大的药物。
Under President Joe Biden's Inflation Reduction Act (IRA), the prices of 10 popular Medicare drugs will be reduced by up to 79% in 2026.
根据乔·拜登总统的通胀减少法案（IRA），2026年将减少10种热门医疗保险药物的价格高达79%。
This move has faced resistance from the pharmaceutical industry, which argues that such measures could stifle innovation. Government officials, however, maintain their commitment to reducing healthcare costs.
这一举措遭到了药品行业的抵制，他们认为此类措施可能会扼杀创新。然而，政府官员坚持承诺降低医疗保健费用。
Despite concerns about the impact on pharmaceutical companies, a Reuters report suggests the financial blow might be less severe than anticipated.
尽管对药品公司的影响存在担忧，路透社的一份报告表明，财务打击可能会比预期的要轻。
Company executives appear to be cautiously optimistic. Pfizer's Chief U.S. Commercial Officer, Aamir Malik, stated that the timing of patent expirations for Ibrance and Xtandi could allow the company to manage the price negotiations effectively.
公司高管似乎持谨慎乐观态度。辉瑞公司美国首席商业官Aamir Malik表示，Ibrance和Xtandi专利到期的时机可能使公司能够有效地处理价格谈判。
Similarly, Teva CEO Richard Francis acknowledged the potential impact of price cuts but remained confident in Austedo's growth prospects, forecasting $2.5 billion in earnings by 2027.
同样，梯瓦制药CEO Richard Francis承认价格下调的潜在影响，但对Austedo的增长前景保持信心，预计到2027年收入将达250亿美元。
Abbvie's CEO expressed a similar sentiment, indicating that their long-term outlook remains intact, even considering future negotiations.
艾伯维公司的CEO表达了类似的看法，表示他们的长期展望仍然完好，甚至考虑未来的谈判。
Regulators will announce up to 15 more drugs for negotiation in 2028, potentially expanding the scope to include medications covered under Medicare's Part B program.
监管机构将在2028年宣布多达15种药品进行谈判，有可能扩大范围以包括医疗保险Medicare的B部分计划下的药物。
As drug negotiations progress, the Congressional Budget Office estimates that savings from the IRA will rise to $9.4 billion by 2027, marking a significant step in the government's effort to reduce healthcare costs.
随着药品谈判的推进，国会预算办公室估计，到2027年，从IRA中的节省将上升到940亿美元，这标志着政府减少医疗成本的重大一步。
Price Action: NVO stock is down 0.64% at $136 at last check Friday.
股价走势：NVO股价在最近一次检查时下跌0.64%，报136美元。周五。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
- Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
- 为什么诊断测试供应商applied dna sciences股票周五交易更高？
Image By Natalia Varlei On Shutterstock
图片来自Natalia Varlei的Shutterstock